While the luminal and HER-2 overexpression types of breast cancer are responsive to targeted treatments, systemic chemotherapy is still the main form of routine treatment for basal-like breast cancer [9], which is characterized by poor prognosis [10]. The gene discussed is ERBB2; the disease is breast cancer.